AAP
STLN

Arax Advisory Partners’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Arax Advisory Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.1K Buy
+28,706
New +$88K ﹤0.01% 1452
2025
Q4 		– Sell
-14
Closed -$49 – 4524
2025
Q3 		$49 Buy
+14
New +$48 ﹤0.01% 3534

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's STLN Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 28,706 shares worth $88.1K. The stake represents ﹤0.01% of the portfolio and ranks #1452 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in STLN as recently as Q3 2025.

Arax Advisory Partners first reported a position in STLN in Q3 2025 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Arax Advisory Partners held 28,706 shares of Starling Oncology Institute, Inc. Common Stock worth $88.1K as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Arax Advisory Partners position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1452 holding.
  • Arax Advisory Partners first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2025 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.